Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 38, Issue 3, 2013, Pages 209-215

  Zhang, Dan ^a   Zhang, Yanan ^a   Liu, Man ^a   Wang, Xiaolin ^a   Yang, Man ^a   Han, Jing ^a   Liu, Huichen ^a  

^a AEROSPACE CENTER HOSPITAL   (China)

Author keywords

5 Hydroxy lansoprazole; Drug accumulation; Intravenous infusion; Lansoprazole; Lansoprazole sulfone; Pharmacokinetics

Indexed keywords

5' HYDROXY LANSOPRAZOLE; CYTOCHROME P450 2C19; DNA; DRUG METABOLITE; LANSOPRAZOLE; LANSOPRAZOLE SULFONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SEX DIFFERENCE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LANSOPRAZOLE; MALE; PROTON PUMP INHIBITORS; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84890312879     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-012-0115-8     Document Type: Article

References (16)

1. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
2. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492
3. Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI (1993) Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36:391-398
4. Inoue M, Nakamura M (1995) Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring. J Clin Gastroenterol 20:S17-S21
5. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391-396
6. Khalique SC, Cheng-Lai A (2009) Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 17:198-200
7. Landes BD, Petite JP, Flouvat B (1995) Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28:458-470
8. Leontiadis GI, Sharma VK, Howden CW (2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. Br Med J 330:568-570
9. Li XQ, Andersson TB, Ahlström M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827
10. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295
11. Ogawa R, Echizen H (2010) Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 49:509-533
12. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816
13. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727
14. Sakurai Y, Hirayama M, Hashimoto M, Tanaka T, Hasegawa S, Irie S, Ashida K, Kayano Y, Taguchi M, Hashimoto Y (2007) Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. Biol Pharm Bull 30:2238-2243
15. Zhang D, Wang X, Yang M, Wang G, Liu H (2011) Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica 41:511-517
16. Zhang D, Yang M, Liu M, Zhang Y, Wang X, Xiao X, Liu H (2012) Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. Xenobiotica 42:1156-1162